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Abstract. In ocular tissue, arachidonic acid is metabolized by cyclooxygenase to prostaglandins which are
the most important lipid derived mediators of inflammation. Presently nonsteroidal anti-inflammatory drugs
(NSAIDs) which are cyclooxygenase (COX) inhibitors are being used for the treatment of inflammatory
disorders. NSAIDs used in ophthalmology, topically, are salicylic-, indole acetic-, aryl acetic-, aryl propionic-
and enolic acid derivatives. NSAIDs are weak acids with pKa mostly between 3.5 and 4.5, and are poorly
soluble in water. Aqueous ophthalmic solutions of NSAIDs have been made using sodium, potassium,
tromethamine and lysine salts or complexing with cyclodextrins/solubilizer. Ocular penetration of NSAID
demands an acidic ophthalmic solution where cyclodextrin could prevent precipitation of drug and minimize
its ocular irritation potential. The incompatibility of NSAID with benzalkonium chloride is avoided by using
polysorbate 80, cyclodextrins or tromethamine. Lysine salts and α-tocopheryl polyethylene glycol succinate
disrupt corneal integrity, and their use requires caution. Thus a nonirritating ophthalmic solution of NSAID
could be formulated by dissolving an appropriate water-soluble salt, in the presence of cyclodextrin or
tromethamine (if needed) in mildly acidified purified water (if stability permits) with or without
benzalkonium chloride and polyvinyl alcohol. Amide prodrugs met with mixed success due to incomplete
intraocular hydrolysis. Suspension and ocular inserts appear irritating to the inflamed eye. Oil drop may be
a suitable option for insoluble drugs and ointment may be used for sustained effect. Recent studies showed
that the use of colloidal nanoparticle formulations and the potent COX 2 inhibitor bromfenac may enhance
NSAID efficacy in eye preparations.
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INTRODUCTION
Inflammation is the manifestation of vascular and
cellular response of the host tissue to injury. Injury to the
tissue may be inflicted by physical or chemical agents,
invasion of pathogens, ischemia, and excessive (hypersensi-
tivity) or inappropriate (autoimmunity) operation of immune
mechanisms. Inflammation facilitates the immune response
and the subsequent removal of antigenic material and dam-
aged tissue. As soon as the injury is recognized, the mecha-
nisms to localize and clear foreign substances and damaged
tissues are initiated. Further the response is amplified by
activation of inflammatory cells and production of chemical
mediators like acidic lipids e.g. prostaglandins (PGs), throm-
boxanes, leukotrienes; vasoactive amines, cytokines etc (1).
Acidic lipids are produced in the arachidonic cascade.
Arachidonic acid is released from the phospholipid compo-
nent of the cell membrane by the action of phospholipase A2.
The arachidonic acid so produced enters either the cyclo-
oxygenase or lipoxygenase pathway. Activation of cyclo-
oxygenase pathway results in formation of PGs and
thromboxanes, while the lipoxygenase pathway yields eicosa-
noids (hydroxyeicosatetraenoic acid and leukotrienes).
Ocular actions of PGs are manifested in three ways (2).
Firstly, they act on intraocular pressure (IOP). PGE1 &E 2
increase the IOP by local vasodilation and increased perme-
ability of blood aqueous barrier. On the other hand PGF2
lowers the IOP which is attributed to increased uveoscleral
outflow. Secondly they act on iris smooth muscle to cause
miosis.Thirdly,PGscausevasodilationandincreasethevascular
permeability resulting in increased aqueous humor protein
concentration. Corticosteroids, the potent anti-inflammatory
agents elicit their action by blocking the enzyme phospholipase
A2 to inhibit arachidonic acid production, thereby preventing
the synthesis of all the PGs, thromboxanes and eicosanoids. On
the other hand non-steroidal anti-inflammatory drugs
(NSAIDs) exert their anti-inflammatory action by inhibiting
the enzymes cyclooxygenase (COX 1 & COX 2).
The pharmacological approach of management of in-
flammation involves administration of anti-inflammatory
agents. Topical administration of drugs is the most preferred
route for management of ocular inflammations as it provides
higher ocular drug concentrations, avoiding the systemic side
effects associated with the oral administration. However due
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inflammatory agents which possess certain physicochemical
properties can be formulated into a suitable dosage form
effective for the management of ocular inflammations.
Corticosteroids used to be the mainstay of topical therapy in
the management of ocular inflammations (3), but their anti-
inflammatory effect was outweighed by serious adverse
effects like elevation of intraocular pressure, progression of
cataracts, increased risk of infection and worsening of stromal
melting (4). As a class, NSAIDs have proven to be a safe and
effective alternative to corticosteroids in the topical manage-
ment of ocular inflammations (5). Currently these drugs are
used topically very widely in inhibition of intra-operative
miosis, management of post-operative inflammation, treat-
ment of seasonal allergic conjunctivitis, prevention and
treatment of cystoid macular edema and in the control of
pain after photo refractive keratectomy (6). NSAIDs have
also been found to be useful in decreasing bacterial coloni-
zation of contact lenses and prevent bacterial adhesion to
human corneal epithelial cells (7).
NSAIDs comprise of several chemically heterogeneous
class of drugs which possess potent cyclooxygenase inhibitory
activity. However, the topical use of NSAIDs in ophthalmol-
ogy is limited to relatively water soluble salicylic acid, indole
acetic acid, aryl acetic acid, aryl propionic acid and enolic acid
derivatives (Table I). Most of the NSAIDs are weakly acidic
drugs, which ionize at the pH of the lachrymal fluid and
therefore have limited permeability through the anionic
cornea which has an isoelectric point (pI) of 3.2 (8). Reducing
the pH of the formulation increases the unionized fraction of
the drug which enhances permeation. Being acidic, NSAIDs
are inherently irritant (6) and reducing the pH of formulation
further increases their irritation potential, as well as decreas-
ing their aqueous solubility. In addition, the anionic nature of
NSAIDs lends to the formation of insoluble complexes with
cationic quaternary ammonium preservatives, such as benzal-
konium chloride (9,10). Thus; it has proved difficult to
formulate topical NSAID formulations that are comfortable
when applied topically to the eye. The present article gives an
insight into various approaches used in topical ocular delivery
of NSAIDs.
SALICYLIC ACID DERIVATIVE
Aspirin
Aspirin, 2-acetoxybenzoic acid, is slightly soluble in water
and freely soluble in alcohol. Topically administered aspirin
was found to significantly block arachidonic acid-induced
lid closure and chemosis in rabbits (11) and inhibit the rise
in secondary aqueous protein concentration as a result of
paracentesis-induced blood aqueous barrier breakdown in
dogs (12). In a comparative study on argon laser iris
photocoagulation-induced miosis, rise in IOP and breakdown
of blood aqueous barrier both topical aspirin (1%, wt/vol) and
indomethacin (1%, wt/vol) were equally effective in inhibiting
the rise in aqueous humor protein concentration and IOP,
while only aspirin showed its inhibitory effect on pupillary
response (13). In the treatment of pollen-induced allergic
conjunctivitis topically administered aspirin (1%, wt/vol) eye
drops were found to be clinically efficacious and safe (14).
Aspirin has been reported to delay progression of
cataracts by inhibiting aldose reductase (15). A topical
formulation of aspirin lysine (0.3%, wt/vol) has been found
to offer protection against galactosemic cataract in rats (16).
The feasibility of transscleral, coulomb controlled iontopho-
retic mode for delivery of aspirin into vitreous chamber was
investigated and compared with intravenous and topical
routes (17). No clinical or histological tissue damage was
observed following the topical or coulomb controlled ionto-
phoretic modes of delivery. Further the results showed that
higher concentrations of salicylic acid were achieved in all the
tissues with coulomb controlled iontophoretic mode of
delivery as compared to the topical and intravenous admin-
istration. The salicylic acid concentration in tissues of the
posterior segment of eye was significantly lower with topical
administration as compared to coulomb controlled iontopho-
retic or IVadministration. The study concluded that coulomb
controlled iontophoretic method of aspirin administration to
the eye is safe and effective with avoidance of systemic side
effects associated with IV administration.
INDOLE ACETIC ACID DERIVATIVES
Indomethacin
Indomethacin, [1-(4-chlorobenzoyl)-5-methylindol-3-yl]
acetic acid, has been used topically as 0.5 or 1% (wt/vol) eye
drops to prevent miosis during cataract surgery and to prevent
cystoid macular edema (18). It is practically insoluble in water,
and has been used in ophthalmology as aqueous solutions of
sodium and tromethamine salt (19). Indomethacin is unstable
in alkaline media and poorly soluble in acidic media,
precipitating out of solution when the pH of the formulation
is below 6.0. Indomethacin ophthalmic suspension buffered to
pH 5.6 containing polyvinyl alcohol or hydroxypropyl methyl-
cellulose (HPMC) as viscolizer was found to be physically and
chemically stable (20). Attempt was made to prepare indo-
methacin (0.1%, wt/vol) aqueous formulation using Polox-
amer-407 as solubilizer. The formulation was found to be
stable, provided higher aqueous humor drug level and
produced a faster resolution of symptoms of inflammation in
immunogenic uveitis model as compared to the marketed
formulation (21). Evaluation of a model aqueous ophthalmic
formulation comprising indomethacin (0.5%, wt/vol), buffered
to pH of 6.8 and solubilized using Pluronic F68, Pluronic
F127 or polysorbate as solubilizer has been described (22).
Pluronics solubilized formulations were observed to give
chemically stable thermo-reversible gels, providing prolonged
diffusion.
To overcome the poor ocular availability and local side
effects of indomethacin, formulations based on oily suspen-
sion and oily emulsion have been evaluated. Aqueous humor
penetration ofindomethacin from oilysuspension(1%,wt/vol)
was found to be significantly higher compared with an aqueous
suspension (1%, wt/vol) (23). For absorption, the drug will
have to partition out of the oil into the aqueous phase.
Prolonged residence of oily suspension in the conjunctival
sac and favorable partition characteristics of the drug could
account for the higher aqueous humor penetration of
indomethacin from oily suspension compared with the
aqueous suspension. Indomethacin, incorporated into
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lized by combination of phospholipids and an amphoteric
surfactant, with pH of aqueous phase adjusted to 3.8 was
evaluated for corneal permeation through excised rabbit
cornea (24). The apparent corneal permeability of indometh-
acin from the emulsion was found to be 3.8 fold higher than
the conventional marketed aqueous formulation. The higher
permeation of indomethacin from the emulsion was attributed
to lower pH of the emulsion, providing a greater unionized
lipophilic fraction of the drug. However, in vivo, the lower pH
Table I. Physicochemical (102,18) and Biopharmaceutical Characteristics of NSAIDs
Drug Structure pKa Mol 
wt
Log 
P
Relative
aqueous humor
bioavailability/conc
Ref. 
No
SALICYLIC ACID DERIVATIVE
Aspirin
O
O
CH3
COOH
3.5 180.2 -1.1
INDOLE ACETIC ACID DERIVATIVES
1.00 (Topical)
 a
0.28 (IV)
3.07 (Iontophoresis)
17
Indomethacin N
H3CO
CH3
COOH
Cl
O
4.2 357.8 4.5
1(Aq. soln.)
b
3(Nanoparticle)
3(Nanocapsule)
3(Nanoemulsion)
26
Bendazac
N
N
O
OH O
--- 282.3 --- -
ARYL ACETIC ACID DERIVATIVES
Diclofenac
H
N
Cl
Cl
COOH
4.2 296.1 4.5
1.0 (Aq. soln.)
a
2.1 (Liposomes)
43
Ketorolac
O
N
COOH 3.49 376.4 2.32.
1.0 (Aqueous)
b
3.16 (Soybean oil)
3.26 (Sesame oil)
50
Nepafenac
NH2 H2NOC
O
--- 254.2 --- -
Bromfenac
NH2 HOOC
Br
O
4.29 383.1 3.22 -
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O
N
COOH
H3C
CH3
3.5 257.3 2.8
1.0 (Conventional)
 b
2.6 (Mucoadhesive)
66
ARYL PROPIONIC ACID DERIVATIVES
Ibuprofen CH3
H3C
CH3
COOH 4.4 206.3 4.0
1.0 (Conventional)
a
1.6 (Nanosuspension)
70
Flurbiprofen
F
COOH
CH3 4.22 244.3 4.2
1.0 (0.15% w/v soln.)
b
0.7(0.3% w/v soln.)
73
Ketoprofen
CH3
COOH
O
4.5 254 --- -
Naproxen
H3CO
CH3
COOH 4.2 230.3 3.2 -
Oxaprozin
N
O COOH
4.3 293 4.8 -
103
Pranoprofen
NO
COOH
CH3
--- 255 --- -
Suprofen
S
COOH
CH3
O
3.9 260 2.8
1(0.5% w/v soln.)
 b
2(1.0% w/v soln.)
94
ENOLIC ACID DERIVATIVE
Piroxicam
N
S
NH
OH N
O O
CH3
O
6.3 331.3 3.1 -
Drug Structure pKa Mol 
wt
Log 
P
Relative
aqueous humor
bioavailability/conc
Ref. 
No
Table I (Continued)
aAqueous humor Cmax
bAqueous humor AUC
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lachrymal fluid upon instillation to the eye. This will result in
pH-inducedlachrymation and lossofdrug fromtheconjunctival
sac resulting in reduced bioavailability. Return of the pH of
lachrymal fluid back to physiological range will reduce ocular
penetration of drug due to ionization. Thus the lower pH of the
emulsion may not offer a net benefit in absorption in vivo.
Polyepsilon caprolactone based nanoparticle, nanocap-
sule and nanoemulsion formulations of indomethacin, of
mean size 225 nm, prepared by interfacial deposition, nano-
precipitation and spontaneous emulsification have been
reported (25). In vitro comparison of colloidal carriers with
commercial eye drops revealed a threefold higher corneal
penetration of indomethacin from colloidal systems. Further,
in vivo evaluation of these colloidal systems in rabbit eye,
showed a threefold higher drug concentration in aqueous
humor at 0.5 h post instillation and a 300% increase in ocular
availability of indomethacin compared with a commercial
solution dosage form while a polymer entrapped micropar-
ticle formulation (6.5 μ size) did not increase the ocular
availability (26). The colloidal carriers penetrated the corneal
epithelium by endocytosis without damaging the membrane.
Colloidal nature of the carriers have been suggested to be
responsible for increased ocular availability of indomethacin.
The ocular pharmacokinetics data of nanoformulations sug-
gest aqueous humor t1/2 of indomethacin (65–74 min) does
not increase on instillation of colloidal formulations indicating
inability of the dosage forms to have a prolonged effect.
To prolong the precorneal residence and thus enhance
the ocular availability of topically applied indomethacin
drops, an ion-activated in situ gelling system based on gellan
gum was formulated. The formulation sustained the in vitro
release for 8 h and was found to be therapeutically effective
in uveitis induced rabbit eye model (27).
Ocular inserts (28) and scleral implants (29,30) have
been employed to extend the release rate of indomethacin.
Ocular inserts of indomethacin were fabricated using a
combination of low and high molecular weight polyvinyl
alcohol. The ex-vivo permeation of drug from ocular inserts
was evaluated through excised goat cornea, and it was
observed that physical cross linking of inserts by freeze-thaw
cycling and increase in the proportion of low molecular
weight polyvinyl alcohol decreased the apparent corneal
permeability of indomethacin (28).
Film type scleral implants of indomethacin based on
sodium alginate (29) and gellan gum (30) have also been
formulated. The in vitro release of indomethacin from scleral
implants depended upon the concentration of plasticizer.
Surface cross-linking of the implants by calcium chloride
retarded the in vitro release. In vivo evaluation of scleral
implants in uveitis induced rabbit eye model showed a
marked improvement in the clinical parameters of inflamma-
tion in the implanted eye as compared to the control eye. The
scleral implants of gellan gum and sodium alginate survived in
vivo up to 3 and 2 weeks respectively.
Bendazac
Bendazac, (1-benzyl-1H-indazol-3-yl-oxy)-acetic acid, is
structurally related to indomethacin. Its lysine salt has been
reported to be absorbed better than the parent compound. It
is applied topically as bendazac lysine 0.5% (wt/vol) aqueous
solution for delaying the progression of cataract (31). Topical
application of bendazac is associated with transient burning
sensation.
ARYL ACETIC ACID DERIVATIVES
Diclofenac
Diclofenac, 2(2, 6-dichloroanilino) phenyl acetic acid, has
a poor aqueous solubility. It is usually used as sodium,
potassium and diethylamine salts (32). For ophthalmic use
diclofenac is commercially available as 0.1% (wt/vol) aqueous
solution of its sodium salt. Diclofenac is applied topically in
the eye for the management of pain in corneal epithelial
defects following surgery or accidental trauma, treatment of
postoperative ocular inflammations, chronic non-infectious
inflammations, and prevention of intra-operative miosis
during cataract surgery and for symptomatic relief of seasonal
allergic conjunctivitis (18). At the physiological pH of eye it
primarily exists in ionized form and thus has limited
permeability. A significantly higher corneal permeation of
diclofenac was observed from solutions buffered to a lower
pH (6.0) (10). Since reducing the pH also leads to precipita-
tion, a number of approaches like use of solubilizer like
polyoxyethylene-35-castor oil, and hydroxypropyl-β-cyclo-
dextrin (33) have been employed. In one study n-octenylsuc-
cinate starch has been suggested as an alternative solubilizer
for diclofenac, and was found to give better permeation
across excised porcine cornea than the polyoxyethylene-
35-castor oil solubilized diclofenac sodium solutions (34).
Acidified solutions (pH 6.5) of diclofenac complexed with
cyclodextrins to increase the solubility were reported to
permeate better through porcine cornea than the neutral
(pH 7.0) diclofenac solutions (33). In a patent claim, stable
and non-irritating formulations of NSAIDs e.g. diclofenac,
have been prepared using α-tocopheryl polyethylene glycol
succinate as solubilizer and preserved using benzalkonium
chloride (35). Topical use of diclofenac was reported to cause
severe corneal toxicity including corneal melting (36). This
adverse event was investigated and it was traced to be due to
a possible role of α-tocopheryl polyethylene glycol succinate
solubilizer in causing aberrant expression of matrix metal-
loproteinase enzymes (37). Adjustment of tonicity of aqueous
diclofenac ophthalmic solutions with mannitol was found to
significantly reduce the corneal permeation of diclofenac.
Using a combination of methylparaben and propylparaben as
preservatives has been found to be favorable for corneal
permeation. On the other hand employment of any one of the
preservatives likes sorbic acid, benzyl alcohol, thiomersal and
phenylmercuric acetate has been found to adversely affect the
in vitro corneal permeation of diclofenac (10). Benzalkonium
chloride at 0.01% (wt/vol) concentration is incompatible with
diclofenac 0.1% (wt/vol) solution (10). However, several
marketed diclofenac ophthalmic solutions containing benzal-
konium chloride (0.02%, wt/vol) were clear and the formu-
lations showed enhanced permeation of drug through excised
cornea. Surface tension measurement of the formulations
indicated presence of additional surfactant besides benzalko-
nium chloride which could account for the increased perme-
ation. In an attempt to overcome the poor aqueous solubility
233 Topical Ocular Delivery of NSAIDsof diclofenac and shorter residence time of aqueous drop in
the conjunctival sac, its oily solution has been formulated.
The oil drop of diclofenac free acid (0.2% wt/vol) in sesame
oil provided more extensive apparent in vitro corneal
permeability of diclofenac compared with diclofenac solutions
formulated in arachis, castor, safflower, mustard, soybean,
and sunflower oils. Addition of benzyl alcohol to oil drop
increased permeation further. Partition experiments with oil
drop and phosphate buffer (pH 7.4) indicated increased
partitioning of diclofenac in aqueous phase in presence of
benzyl alcohol. Since only the drug present in aqueous phase
could be absorbed, increased partitioning in aqueous phase
increases corneal permeability from the formulation contain-
ing benzyl alcohol (38).
Apart from the commercially available conventional
dosage form, various other delivery systems like novel
polydisperse carrier solution (Sophisen) (39), ophthalmic gels
(40), ocular inserts (41,42) and liposomes (43) of diclofenac
have been evaluated. Polydisperse carrier solutions of diclo-
fenac were reported to provide better tolerance and sustained
release of diclofenac (39). Diclofenac sodium (0.1%, wt/vol)
ophthalmic gels were formulated using sodium carboxymethyl
cellulose (1%, wt/vol), hydroxypropyl methylcellulose
(HPMC) (4%, wt/vol) or methylcellulose (3%, wt/vol). The
gel formulated using HPMC provided better ocular tolerance
and sustained in vitro drug release up to 9 h (40). Using a
combination of methylcellulose and sodium carboxymethyl
cellulose, ocular insert of diclofenac was also prepared and
was found to be stable and sustain the release of diclofenac
for 12 h (41). In yet another study to improve the intraocular
retention of inserts, mucoadhesive thiolated ocular inserts
comprising of polyacrylic acid-cysteine conjugate as polymeric
matrix, containing either diclofenac sodium or diclofenac-tris
(hydroxymethyl)-amino methane were prepared and evaluated
(42). In vitro release studies conducted using simulated
lachrymal fluid revealed a significantly lesser release of drug
from diclofenac-tris inserts compared with diclofenac sodium
inserts. The inserts were successful in providing a controlled
drug release with release rate approximating zero order release
kinetics. Pre-corneal retention of diclofenac sodium has also
been reported to be increased by use of liposomes. The
cationic liposomes of diclofenac sodium prepared by reverse-
phase evaporation were observed to provide a 211% increase
in aqueous humor concentration of drug compared with
conventional aqueous eye drop formulation (43).
Ketorolac
Ketorolac, 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-car-
boxylic acid, is a racemic mixture. The anti-inflammatory
activity of the levorotatory (l) isomer of the drug is twice that
of dextrorotatory isomer (d)( 44). It is commercially available
as the tromethamine salt which has higher aqueous solubility
compared to ketorolac. Ketorolac is applied topically in the
management of seasonal allergic conjunctivitis, postoperative
ocular pain and inflammation (18). Instillation of ketorolac
tromethamine (0.5%, wt/vol) aqueous solution was associated
with ocular irritation, mainly burning and stinging. To reduce
the incidence of this adverse affect, use of lower concentra-
tion of ketorolac tromethamine (0.4%, wt/vol) has been
advocated (45).
Investigations on the in vitro corneal permeation of
ketorolac revealed that reducing the pH of formulation
increased the corneal penetration of ketorolac, with ketorolac
tromethamine aqueous drop (0.5% wt/vol) formulated in
phosphate buffer (pH 4.5) providing more extensive in vitro
corneal permeation (46). Ketorolac is chemically unstable,
undergoing acid and base catalyzed autooxidation (47). It was
observed that unbuffered ketorolac tromethamine drops of
pH 6.5 to 8.5 provided enhanced chemical stability. Keeping
the stability and corneal permeation of ketorolac in view,
unbuffered ketorolac tromethamine ophthalmic solution
(pH 6.5) was considered optimal (46). Preservation of the
ketorolac aqueous drops with benzalkonium chloride, EDTA,
chlorbutanol, phenylmercuric acetate and phenylmercuric
nitrate was associated with increased corneal permeation
(48). On the other hand preservation with thiomersal was found
to decrease the corneal permeation of ketorolac. Presence of
ascorbic acid, sodium sulphite or citric acid in ketorolac
tromethamine ophthalmic solution had a negative impact on
the corneal permeation of ketorolac, while sodium metabisul-
phite favored corneal permeation. Among all the formulations
ketorolac tromethamine ophthalmic solution (0.5% wt/vol)
containing benzalkonium chloride (0.01% wt/vol) and EDTA
(0.01% wt/vol) provided more extensive permeation.
Apart from the aqueous solutions, oily solution and
ophthalmic ointment preparations of ketorolac have also
been formulated (49). The results show that oil drop of
ketorolac free acid formulated in sesame oil and preserved
with benzyl alcohol provided more extensive in vitro corneal
permeation of ketorolac. Partition experiments between oil
and phosphate buffer (pH 7.4) showed increased partition of
ketorolac into the aqueous phase from sesame oil drop which
could account for the increased permeation. Both ketorolac
free acid and ketorolac tromethamine were formulated as
ointment dosage forms. Formulation containing ketorolac
tromethamine aqueous solution dispersed in ointment base
showed higher in vitro corneal permeation compared to
formulations containing solid ketorolac tromethamine and
ketorolac free acid dispersed in ointment base. Chemical
form and physical state of the drug, thus, could affect ocular
permeation. In vivo comparison of the aqueous, oil and
ointment formulations of ketorolac for ocular availability in
rabbits revealed that the ketorolac drops (0.2%, wt/vol)
formulated in sesame oil and soybean oil provided higher
ocular availability followed by ointment and aqueous for-
mulations (50). The ointment formulation provided pro-
longed precorneal residence and sustained effect. Aqueous
humor t1/2 of ketorolac was 10 h with ointment and 6.6 h with
oil drops. However, the permeation enhancing effect of
benzalkonium chloride and EDTA combination, observed in
the in vitro studies,did not translate into increased ocular
availability during in vivo assessment. The rate of ocular
absorption was increased but not the extent. This may be
attributed to the increased lachrymation induced by ocular
irritant (51) effects of benzalkonium chloride and EDTA.
Pharmacodynamic evaluation of aqueous, oily and oint-
ment formulations of ketorolac in PGE2-induced ocular
inflammation in rabbits established the efficacy of ketorolac
formulations in inhibiting PGE2-induced ocular inflammation.
Prolonged topical use of the formulations did not produce
any gastrointestinal ulceration in rats, a common side effect
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safety of the products on chronic administration (52).
In another study reservoir type ocular inserts of ketorolac
were formulated using HPMC or methylcellulose and povi-
done as polymeric films, and ethylcellulose film as rate
controlling membrane (53). The ocular inserts casted using
HPMC (4%) and ethyl cellulose (3%) were found to sustain
ketorolac tromethamine release by zero order kinetics for 22 h.
To increase the ocular availability, ketorolac was entrap-
ped in N-isopropylacrylamide, vinyl pyrrolidone and acrylic
acid based copolymeric nanoparticles. The particles were
spherical and had a size of 35 nm. In vitro permeation studies
through excised cornea revealed twofold higher permeation
of drug from nanoparticle formulation, compared with an
aqueous suspension of the drug. Pharmacodynamic evalua-
tion of nanoparticle formulation in PGE2-induced ocular
inflammation in rabbits showed a significantly higher ocular
anti-inflammatory activity for 5 h compared with the aqueous
suspension (54), which has been attributed to the small size of
the particles and mucoadhesiveness. The nanoparticle formu-
lation did not show any corneal damage during in vitro study.
Nepafenac
Nepafenac, 2-amino-3-benzoylbenzeneacetamide,is a pro-
drug (55) which rapidly penetrates the cornea. In vitro
permeation studies across the human cornea showed six times
faster penetration of nepafenac than diclofenac. After pene-
trating the cornea nepafenac is deaminated by intraocular
hydrolases to amfenac [(2-amino-3-benzoyl phenyl) acetate], a
potent inhibitor of COX-1 and COX-2 (56). Investigations with
concanavalin-A-induced retinal inflammation in rabbits
revealed a greater degree of inhibition of inflammation with
nepafenac as compared to ketorolac and diclofenac (57). A
recent study compared the PGE2-inhibition and aqueous
humor penetration of ketorolac and nepafenac in patients
undergoing phacoemulsification. The patients received ketor-
olac (0.4% wt/vol) solution or nepafenac (0.1% wt/vol)
suspension four times daily for 2 days before cataract
extraction. Ketorolac showed a significantly greater inhibition
of PGE2 and a higher aqueous humor penetration than the
nepafenac at surgery, which contradicts an earlier finding (58).
The decreased inhibition of PGE2 by nepafenac, was attributed
to the presence of considerable amount of unhydrolysed
nepafenac (prodrug) in the aqueous humor of patients
suggesting inadequate metabolism to amfenac to prevent
inflammation. Thus, it was concluded that the prodrug
character of nepafenac does not confer any advantage with
regard to ocular penetration and PGE2 inhibition. In another
study where patients received nepafenac 0.1% (wt/vol) oph-
thalmic suspension one day before cataract surgery to 14th day
after surgery, nepafenac was found to be effective in preventing
and treating ocular inflammation and pain associated with
cataract surgery (59). During prolonged treatment the metab-
olism of nepafenac appears to be sufficient to produce amfenac
for treating inflammation and pain.
Bromfenac
Bromfenac,2-amino-3-(4-bromobenzoyl) benzene acetic
acid, is structurally identical to amfenac with the exception of
a bromine atom at the C4 position. Introduction of bromine in
bromfenac makes it more lipophilic, facilitating corneal
penetration, increased duration of action and enhanced
COX-2 inhibitory activity (60,61). It is available as sesquihy-
drate sodium salt. Aqueous drops of sodium salt (containing
equivalent of 0.09% wt/vol bromfenac) have been used in the
management of postoperative ocular inflammation and pain
in patients who have undergone cataract extraction (62).
Commercially available formulation is buffered to pH of 8.3
and contains polysorbate 80 as solubilizer and benzalkonium
chloride (0.005%) as preservative. It has a good ocular pene-
tration and significant amounts are also absorbed systemically
on topical administration. Bromfenac has been found to be 3.7,
6.5 and 18 times more potent inhibitor of COX-2 than
diclofenac, amfenac (63) and ketorolac (64) respectively. In
another study involving arachidonic acid- and carrageenan-
induced conjunctival edema in rabbits, bromfenac was found to
be 3.8 and 10.9 times more potent than indomethacin and
pranoprofen as inhibitor of PG production (65).
Tolmetin
Tolmetin, 1-methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-
acetic acid, is usually used as sodium salt which is freely
soluble in water and slightly soluble in alcohol. Ocular anti-
inflammatory activity of aqueous tolmetin (0.5%) ophthalmic
solution was evaluated and compared with a mucoadhesive
formulation of tolmetin in sodium arachidonate-induced
ocular inflammation in rabbits (66). Tolmetin treatment was
found to significantly reduce the signs and symptoms of
ocular inflammation. A significant reduction in sodium
arachidonate-induced aqueous humor PGE2 levels, polymor-
phonuclear leukocytes, protein concentration and IOP rise
was observed in tolmetin treated eyes. The results of the
pharmacokinetic evaluation revealed significantly higher
aqueous humor drug concentrations in inflamed eyes as
compared to uninflamed eyes. Further, the mucoadhesive
formulation of tolmetin provided 2.6- and 2.0-fold higher
aqueous humor area under the concentration-time curve
(AUC) values compared to the aqueous formulation in
uninflamed and inflamed eyes respectively.
ARYL PROPIONIC ACID DERIVATIVES
Ibuprofen
Ibuprofen, 2-(4-isobutylphenyl) propionic acid, is practi-
cally insoluble in water and to overcome its poor aqueous
solubility sodium and lysine salts have been employed (67). In
an in vitro study it was observed that increase in ibuprofen
concentration in aqueous drops reduced the % permeation or
in vitro ocular availability. Increase in concentration of drug
in the corneal epithelial side does not result in proportionate
increase in the amount permeated because only the quantity
of drug needed to saturate corneal epithelium could permeate
through stroma and endothelium. As a result increase in
concentration decreases in vitro ocular availability. Per-
meation of ibuprofen was higher at pH 6.4 and decreased
on increase of pH to physiological range. Benzalkonium chlo-
ride and chlorbutanol increased permeation of ibuprofen.
Benzalkonium chloride (0.01% wt/vol) when mixed with
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indicating formation of less water soluble ion pair due to
cation–anion interaction. Increased permeation of ibuprofen
in the presence of benzalkonium chloride appears to be due
to formation of a more lipid-soluble ion pair (9). In another
study, 2(4-hydroxyethoxy phenyl) acetic acid and 2(4-hydrox-
yethoxy phenyl) propionic acid, the more water soluble
structural analogs of ibufenac and ibuprofen demonstrated
3.3-fold lesser apparent corneal permeability coefficient than
their parent compounds in rabbit eye (68). In vivo evaluation
of ocular anti-inflammatory activity of ibufenac and ibuprofen
structural analogs against clove oil or arachidonic acid-
induced inflammation showed the anti-inflammatory activity
to decrease in the order of ibufenac > ibuprofen > 2(4-
hydroxyethoxy phenyl) acetic acid > 2(4-hydroxyethoxy
phenyl) propionic acid. The hydroxyethoxy analogs had a
60-fold greater aqueous solubility and 1/1500 fold less lipid
solubility compared to ibufenac and ibuprofen. Considering
the lipophilicity of the three layers of the cornea: epithelium
(lipophilic), stroma (hydrophilic) and endothelium (less
lipophilic than epithelium), it can be reasoned that a drug
that possesses high lipid solubility but poor aqueous solubility
will not be able to penetrate beyond corneal epithelium while
a highly water soluble drug having limited lipid solubility will
not be able to penetrate corneal epithelium unless assisted by
a carrier. Hence for corneal penetration, a drug must have a
balanced solubility in both water and lipid. The reduced
corneal permeability/anti-inflammatory activity of the
hydroxyethoxy analogs of ibufenac and ibuprofen appears
to be due to reduced lipid solubility. Topical application of
ibuprofen and ibufenac was associated with local irritation
and ocular discomfort, which was attributed to the higher
surface activity of the compounds.
In a recent study, ibuprofen amino acid compounds were
evaluated for their emulsifying and cytotoxic properties. It
was observed that different ibuprofen salts possess surface
activity in the order of ibuprofen lysinate > ibuprofen sodium >
ibuprofen arginate > ibuprofen histidinate (69). The hemolytic
behavior of ibuprofen salts correlated with their surface
activity. Histological examination of excised porcine corneas
treated with solutions of ibuprofen salts revealed ibuprofen
histidinate as least cytotoxic, while lysinate and arginate
salts were found to adversely affect the corneal integrity.
Cationic amino acid salts of drug thus appear to be detri-
mental to the anionic cornea and caution is needed while
using lysine salt which is most commonly used for topical
delivery. However, treatment of excised porcine corneas
with emulsions of ibuprofen lysinate and arginate did not
affect the corneal integrity.
In order to improve ocular availability, ibuprofen loaded
polymeric nanoparticle suspensions were made from Eudragit
RS 100 by a quasi emulsion solvent diffusion technique. The
nanosuspension inhibited the miotic response to ocular
trauma (paracentesis) in rabbits comparable to a control
aqueous formulation. The nanosuspension showed a mean
size of 100 nm and a positive charge which helps in corneal
adhesion. A gradual and prolonged release of the drug
associated with increased retention on the corneal surface
resulted in a higher aqueous humor drug level compared with
an aqueous solution. The nanosuspension did not show any
ocular tissue toxicity (70).
Flurbiprofen
Flurbiprofen, 2-(2-fluorobiphenyl-4-yl) propionic acid, is
practically insoluble in water. Aqueous solutions of flurbipro-
fen sodium (0.03% wt/vol) are employed to inhibit intra-
operative miosis during cataract surgery and to control
postoperative inflammation of the anterior segment of the
eye (18). Flurbiprofen sodium eye drops have also been used
in the topical treatment of cystoid macular edema. Flurbipro-
fen ophthalmic solution USP has a recommended pH of 6–7.
The S-(+) isomer of flurbiprofen has been found to be 100
times more potent inhibitor of prostaglandin synthesis than
the R-(−) isomer (71). In one of the studies, preservative-free
aqueous eye drops of RS(±)-flurbiprofen (0.03%, wt/vol), S
(+)-flurbiprofen (0.015%, wt/vol) and R(−)-flurbiprofen
(0.015%, wt/vol) were formulated using phosphate buffer
(0.13 M, pH 7.4) as the vehicle and packaged in glass
containers (72). The formulations were found to have a shelf
life of 4 years, and in vitro enantiomeric inversion was not
detected. The S (+)-flurbiprofen (0.015%, wt/vol) drops were
found to produce inhibition of PG synthesis comparable to
RS (±)-flurbiprofen (0.03%, wt/vol) eye drops. Studies on in
vitro corneal permeation of flurbiprofen have revealed that
increase in the concentration of drug in aqueous drops
decreased the % permeation or in vitro ocular availability.
Permeation of flurbiprofe nw a sh i g h e ra tp H6 . 4a n d
decreased on increase of pH to physiological range. Perme-
ation of flurbiprofen was enhanced by benzalkonium chloride
due to formation of more lipid soluble ion-pair between
anionic flurbiprofen and cationic benzalkonium chloride
which develops opalescence. Phenylmercuric nitrate also
enhanced corneal permeation of flurbiprofen (9). An in vivo
study, which reported 30% greater ocular availability of
flurbiprofen from flurbiprofen (0.15%, wt/vol) topical aque-
ous drop compared with flurbiprofen (0.30%, wt/vol) topical
solution, supports the in vitro data on the effect of drug
concentration on corneal permeation (73). Flurbiprofen
solutions of concentration greater than 0.2% (wt/vol) are
quite irritating. A topical aqueous flurbiprofen ophthalmic
formulation comprising of γ-o rβ-cyclodextrin to achieve
higher solubility of flurbiprofen has been disclosed in a patent
claim (74). The formulation was found to be non-irritating
even in the presence of higher concentrations of flurbiprofen.
As compared to the conventional flurbiprofen solution,
formulations containing cyclodextrin provided a greater
inhibition of increase in blood-aqueous barrier permeability
after cataract operations. Reducing the pH of cyclodextrin
containing flurbiprofen formulation from 8.0 to 5.3 provided a
2.7 fold increase in intraocular permeation of flurbiprofen in
rabbit’s aqueous humor, whereas in case of conventional
formulation, 2.2 fold increases were observed. The improve-
ment in intraocular permeability of cyclodextrin-containing
formulation at lower pH was attributed to its much lesser
irritation potential. Further the results reveal a 1.5 fold
greater intraocular permeation of flurbiprofen from formu-
lations containing viscolizers (HPMC or hydroxy ethyl
cellulose, 0.2%, wt/vol) as compared to formulation without
viscolizers.
A patent claim (75) describes the amide derivatives of
amfenac, bromfenac, diclofenac, ketorolac, flurbiprofen and
suprofen for treatment of ocular inflammation. In vitro
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higher apparent permeability coefficient for amide derivatives
of amfenac and diclofenac compared to the rest. However the
amide derivatives of bromfenac, diclofenac and suprofen
were resistant to hydrolytic bioactivation in the iris-ciliary
body. The amide derivatives of amfenac and flurbiprofen
significantly inhibited paracentesis-induced blood aqueous
barrier breakdown (75).
In an attempt to improve the ocular availability, flurbi-
profen-loaded cationic polymeric nanoparticle suspensions, of
mean size 100 nm, were prepared from Eudragit RS 100 and
RL 100 using quasi emulsion solvent diffusion technique. In
vitro dissolution tests showed a controlled release profile of
flurbiprofen from the nanoparticles. In vivo investigation of
the flurbiprofen loaded RS nanosuspension in paracentesis-
induced miosis in rabbits indicated an efficacy comparable to
control eye drop formulation. The nanosuspension also
provided higher aqueous humor drug level. The formula-
tion did not show any sign of toxicity or irritation to ocular
tissue (76).
Biodegradable flurbiprofen nanoparticles based on poly
(lactic/glycolic) acid have also been prepared using solvent
displacement technique. The nanosuspensions were found to
possess excellent ocular tolerance. Further the prepared
flurbiprofen nanosuspension was found to afford significant
protection against sodium arachidonate-induced inflamma-
tion in rabbit eyes (77).
Ketoprofen
Ketoprofen, 3-benzoyl-α-methylbenzeneacetic acid, is a
racemic mixture. The S (+) enantiomer of ketoprofen has
twice the activity of the racemic mixture. The ocular anti-
inflammatory activity of topical ketoprofen (0.01%, wt/vol)
was evaluated in rabbit corneal epithelial wound model (78).
Topical ketoprofen was observed to inhibit PG synthesis in
conjunctiva and iris-ciliary body, and to prevent the release of
polymorphonuclear leukocytes into the tear fluid of rabbits.
Further it did not interfere with wound healing after complete
corneal de-epithelialization in rabbits.
Naproxen
Naproxen, (+)-2-(6-methoxy-2-naphthyl) propionic acid,
is practically insoluble in water. A study reports the use of
oxyethylated methyl esters of rape oil fatty acids (Rofams) as
solubilizer in naproxen eye drops (79). Topical administration
of aqueous naproxen sodium eye drops was found to provide
a significant protection against sodium arachidonate-induced
rise in aqueous humor PGE2, protein and polymorphonuclear
leukocytes (80). Naproxen was also found to afford protec-
tion in rabbits against inflammatory response induced by
anterior chamber paracentesis (81). In a comparative study,
naproxen sodium (0.2%, wt/vol) drops were found to be as
effective as diclofenac sodium (0.1%, wt/vol) drops in control-
ling post operative inflammation after uncomplicated cataract
surgery (82). Naproxen (0.1%, wt/vol and 0.2%, wt/vol) eye
drops were explored for controlling ocular inflammation in
patients having phacoemulsification and intra ocular lens
implantation (83). Naproxen eye drops were found to be
safer and tolerable. Further, naproxen (0.2%, wt/vol) drops
were reported to be more efficacious than the naproxen
(0.1%, wt/vol) drops in controlling the signs and symptoms
of ocular inflammation.
Oxaprozin
Oxaprozin, 3-(4, 5-diphenyloxazol-2-yl)-propionic acid, is
slightly soluble in alcohol and insoluble in water. Oxaprozin
(0.1%, wt/vol) aqueous eye drops significantly protected
rabbits against arachidonate-induced conjunctival inflamma-
tion and iris hyperemia (84), and arachidonate-induced rise in
protein and polymorphonuclear leukocytes concentration in
the aqueous humor. Pharmacokinetic evaluation for aqueous
humor bioavailability of oxaprozin revealed that peak aque-
ous drug levels were achieved 60 min post-instillation.
Further a 4-fold higher aqueous humor bioavailability was
observed in inflamed eyes as compared to control eyes. In
another study diethylene glycol monoethyl ether (Transcutol
P) was evaluated as permeation enhancer (0.005–0.03%) for
oxaprozin using isolated rabbit cornea (85), and it was found
to increase the lag time and decrease the apparent corneal
permeability of oxaprozin, with maximum decrease of 2.8-
fold at a concentration of 0.03%. The decreased corneal
permeability of lipophilic oxaprozin was attributed to corneal
hydration barrier.
Pranoprofen
Pranoprofen, α-methyl-5H-[1]-benzopyrano [2,3-b]-pyri-
dine-7-acetic acid, is applied topically as 0.1% (wt/vol)
aqueous solution in the management of ocular inflammations.
Topically applied pranoprofen has been demonstrated to
possess analgesic and ocular anti-inflammatory activity com-
parable to flurbiprofen in endotoxin-induced uveitis model
(86). It has also been found to be as effective as diclofenac
sodium(0.1%, wt/vol) in reducing pain and inflammation after
strabismus surgery (87).
Pre-treatment with mydriatic eye drops comprising of
tropicamide (0.5%, wt/vol) and phenylephrine (0.5%, wt/vol)
was found to provide 2- to 3-fold higher intraocular concen-
tration of pranoprofen (88). Investigation on the mechanism of
mydriatic-induced increased permeation of pranoprofen
showed phenylephrine to be responsible for increased
corneal permeation. Further it was observed that mixing
phenylephrine with pranoprofen increased octanol/buffer
partition coefficient of both pranoprofen and phenyleph-
rine. The increased permeation of pranoprofen in presence
of phenylephrine was attributed to formation of more
lipophilic ion-pair between anionic pranoprofen and cat-
ionic phenylephrine.
Pranoprofen is inherently irritating to the eye. It was
observed that adjustment of isotonicity by boric acid provides
the formulation with least irritation potential as compared to
tonicity adjustment with sodium chloride, mannitol or glycer-
ine (89). Pranoprofen is chemically unstable as it undergoes
photochemical oxidation in aqueous solution. A stable
aqueous formulation of pranoprofen utilizing butylated
hydroxyanisole/butylated hydroxytoluene/methionine/trypto-
phan as antioxidants has been described in a patent claim
(90). Pranoprofen is incompatible with benzalkonium chlo-
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ity polysorbate 80 has been utilized as the solubilizer (91). It
was found that the incompatibility between benzalkonium
chloride and pranoprofen can be avoided by adding benzal-
konium chloride to pranoprofen in the presence of trometh-
amine. Further addition of tromethamine to pranoprofen
solution reduced the ocular irritation of pranoprofen.
Suprofen
Suprofen, α-methyl-4-(2-thienylcarbonyl) benzene acetic
acid, is sparingly soluble in water. Suprofen ophthalmic
solution USP consists of suprofen dissolved in a buffered
isotonic vehicle having a pH of 6.5–8.5. Suprofen 1% (wt/vol)
eye drops are applied topically to inhibit the intra operative
miosis during ocular surgery (18). Suprofen eye drops have
been found to be useful in treatment of contact lens-
associated giant papillary conjunctivitis (92). Suprofen does
not interfere with the stromal wound healing (93). Suprofen
eye drops may cause local reactions including discomfort,
itching, pain and photophobia. In an ocular bioavailability
study in rabbits, suprofen 1.0% (wt/vol) drop provided a 2-
fold higher ocular bioavailability of suprofen compared with
eye drop of 0.5% (wt/vol) concentration (94). However there
was no significant difference in corneal anti-inflammatory
effect of suprofen between these concentrations against clove
oil-induced corneal inflammation. In a comparative study
involving suprofen, tolmetin, flurbiprofen and diclofenac in
treatment of experimental blood aqueous barrier disruption in
dogs, suprofen was found to be more efficacious than tolmetin
but less efficacious than diclofenac and flurbiprofen (95).
Suprofen is a racemic mixture with 70% of its activity
due to its (+)-enantiomer (96). An ophthalmic formulation of
half strength (+)-suprofen is devoid of acute stinging sensa-
tion associated with full strength (±)-suprofen. Further, the
use of pentanediol ester and butylamine amide derivatives of
(+)-suprofen free from corresponding (−)-suprofen species as
ophthalmic anti-inflammatory agents have been reported
(96). These derivatives have been claimed to provide
improved ocular bioavailability of suprofen. However in vivo
data regarding the intraocular hydrolysis of the derivatives or
their anti-inflammatory activity were not provided (96).
ENOLIC ACID DERIVATIVE
Piroxicam
Piroxicam, 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2–
benzothiazine-3-carboxamide-1, 1-dioxide, is practically insol-
uble in water and dilute acids, slightly soluble in alcohol and
in aqueous alkaline solutions. Topical ophthalmic formula-
tions have employed cyclodextrins as complexing agents to
improve the solubility (97). Topical application of piroxicam
(0.5%, wt/vol) eye drops was found to be effective in reducing
aqueous PGF2 levels in experimental uveitis in rabbits (98).
Pre-treatment with topical piroxicam (0.5%, wt/vol) in
glaucoma patients undergoing argon trabeculoplasty effec-
tively inhibited ocular PGE2 synthesis (99). Topical piroxicam
(0.5%, wt/vol) was also found to possess ocular anti-
inflammatory activity comparable to diclofenac sodium
(0.1%, wt/vol) and indomethacin (0.1%, wt/vol), and ocular
tolerance better than diclofenac sodium (0.1%, wt/vol) (100).
To improve the ocular delivery of piroxicam, nano-
suspensions were prepared using Eudragit RS100 as the
polymer (101). The prepared nanosuspension was found to
release the drug by diffusion. In endotoxin induced uveitis
model, the nanosuspension provided a significant inhibi-
tion of inflammation compared with a microsuspension of
drug alone.
CONCLUSIONS
A number of NSAIDs have been formulated as aqueous
solutions for ocular delivery using sodium, potassium, tro-
methamine and lysine salts or complexing with cyclodextrins/
solubilizer to improve aqueous solubility. Ocular penetration
of NSAID demands an ophthalmic solution of acidic pH
which could precipitate the drug or increase its ocular
irritation potential and cyclodextrins could solve both the
problems. The incompatibility of NSAID with benzalkonium
chloride, a cationic preservative, commonly used in eye drops,
is avoided using polysorbate 80, cyclodextrins or trometh-
amine. Lysine salts and α-tocopheryl polyethylene glycol
succinate disrupt corneal integrity; solubilizers are irritating,
hence caution is needed in their use. Thus a nonirritating
ophthalmic solution of NSAID could be formulated by
dissolving an eye-friendly water soluble salt, cyclodextrin
or tromethamine and an antioxidant, if needed, in mildly
acidified purified water, if stability permits, with or without
benzalkonium chloride. In case of a drug that is insoluble
in water, cyclodextrin or tromethamine could be used as
solubilizer. Polyvinyl alcohol appears to be a good viscol-
izer. Amide prodrugs appear to be efficacious for some
NSAIDs while ineffective for others due to incomplete
hydrolysis in intraocular tissue. Suspension and ocular
inserts appear to be irritating to inflamed eye. Oil drop for-
mulation could be considered as a suitable option for water
insoluble drugs while ointment for sustained effect. Colloidal
nanoparticle formulations are most promising for ocular
delivery. As topical ocular anti-inflammatory agent, bromfenac,
the most potent COX-2 inhibitor holds promise. Nanoparticle
formulations of bromfenac could be tried for topical delivery
to the eye.
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